Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLR1A | O95602 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588483 | 0.99 | MEN1 (0.51) | KDM4ELMNAMEN1KMT2APOLB | |
| SCHEMBL19849358 | 0.86 | MEN1 (0.52) | KDM4ELMNAMEN1KMT2APOLB | |
| SCHEMBL20879965 | 0.85 | MEN1 (0.54) | KDM4ELMNAMEN1KMT2APOLB | |
| SCHEMBL12333392 | 0.84 | POLB (0.62) | KDM4ELMNAMEN1KMT2APOLB | |
| SCHEMBL12305551 | 0.80 | MEN1 (0.56) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL47618 | 0.80 | SIGMAR1 (0.53) | — | |
| SCHEMBL47616 | 0.79 | SIGMAR1 (0.52) | — | |
| SCHEMBL18588481 | 0.78 | POLR1A (0.48) | MEN1KMT2APOLR1A | |
| SCHEMBL24333908 | 0.78 | NPSR1 (0.56) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL13164061 | 0.78 | NPSR1 (0.59) | MEN1KMT2APOLBNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | KDM4E 4186/4885LMNA 1992/4885MEN1 3163/4885 |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4E 2150/4885LMNA 1914/4885MEN1 402/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4E 2150/4885LMNA 1914/4885MEN1 402/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KDM4E 1756/4885LMNA 3156/4885MEN1 4821/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | KDM4E 3663/4885LMNA 1817/4885MEN1 1495/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KDM4E 1424/4885LMNA 194/4885MEN1 1318/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | KDM4E 1756/4885LMNA 3156/4885MEN1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.